CERTIFICATE OF ANALYSIS

TESTED PEPTIDE: **RETATRUTIDE + TIRZEPATIDE**

Scan to Verify COA Authenticity



SAMPLE INFORMATION

Sample Name:
Reratrutide 20mg + Tirzepatide 40mg

Lot Number:
260924

Sample Matrix:
Lyophilized Peptide

Received Date:
September 24, 2026

Sample ID:
1538.OPT.260924

Client:
BDLABS

Intended Use:
Research Use Only

Report Date:
October 1, 2026

IDENTITY
RETATRUTIDE + TIRZEPATIDE
LC-MS

NET CONTENT
20.25/40.33 MG/VIAL
HPLC

PURITY
99.6%
RP-HPLC

ENDOTOXIN
PASS
LAL

RESULTS SUMMARY

TEST PANEL	METHOD	SPECIFICATION	RESULT	STATUS
Identity Verification	LC-MS	Confirmation	Retatrutide + Tirzepatide	TESTED
Net Content	HPLC	-	20.25/40.33 mg/vial	TESTED
Purity	RP-HPLC	≥ 95%	99.6%	TESTED
Endotoxin	LAL	≤ 0.05 EU/mg	Pass	PASS

QUALITY GUARANTEED

Analyst
Bryan Zahakaylo
Date: October 1, 2026

ND = Not Detected, NR = Not Reported, LOD = Limit of Detection, and LOQ = Limit of Quantitation. Results reported herein relate only to the specific sample tested. Optiq Health Labs, LLC makes no claims regarding the efficacy, safety, suitability, purity, sterility, or other risks associated with any detected or non-detected compounds, analytes, or reported values. This Certificate of Analysis shall not be reproduced except in full, without the written approval of Optiq Health Labs, LLC. This Certificate of Analysis is limited to the sample received and tested by the laboratory and does not represent or warrant the quality, composition, or characteristics of any other sample, lot, batch, product, or material. Any statements, representations, labeling, or claims regarding the intended use, application, or purpose of the tested material are solely those of the client and do not constitute, imply, or reflect any recommendation, endorsement, certification, or intended use determination by Optiq Health Labs, LLC.

info@optiqhealthlabs.com (949) 841-2437 www.optiqhealthlabs.com 1920 E Warner Avenue Unit N, Santa Ana CA, 92705